在首次缓解6年后，本妥昔单抗单药治疗经典型霍奇金淋巴瘤晚期复发取得成功。
Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission.
作者信息
Nagashima Kana, Kikuchi Shohei, Iyama Satoshi, Fujita Chisa, Goto Akari, Horiguchi Hiroto, Kobune Masayoshi
机构信息
Department of Hematology Sapporo Medical University School of Medicine Sapporo Japan.
出版信息
Clin Case Rep. 2020 Jan 31;8(3):466-468. doi: 10.1002/ccr3.2688. eCollection 2020 Mar.
Abstract
Brentuximab vedotin monotherapy for late-relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.
摘要
本妥昔单抗单药治疗晚期复发的经典型霍奇金淋巴瘤是一种有前景的疗法，可带来持续的完全缓解益处，并避免自体造血干细胞移植/高剂量化疗引起的潜在毒性。
Zotero 插件